miR-485-5p improves the progression of ovarian cancer by targeting SRC in vitro and in vivo.

Research paper by Y Y Yang, J J Liu, X X Qian, Y Y Li, Y Y Wang, X X Xu

Indexed on: 17 Jun '20Published on: 17 Jun '20Published in: Neoplasma


miR-485-5p is involved in many tumors, but its role in ovarian cancer has been rarely reported. This paper mainly studied the expression and mechanism of miR-485-5p in ovarian cancer. The expression of miR-485-5p in ovarian cancer was compared with that in adjacent tissues, and the expression of miR-485-5p in various ovarian cancer cell lines was detected by RT-PCR. miR-485-5p mimics and pcDNA plasmid or pcDNA-SRC were transfected into SKOV3 cells. Cell proliferation was detected by CCK-8, cell cycle and apoptosis were detected by flow cytometry, and cell migration and invasion were detected by wound assay and transwell assay. Nude mice were inoculated with SKOV3 cells to detect the effect of miR-485-5p on xenograft. SRC and its downstream proteins were detected by western blot. Our data suggested that the expression of miR-485-5p was low in ovarian cancer tissues and ovarian cancer cell lines. miR-485-5p mimics can inhibit the proliferation, migration, invasion, and the induction of cycle arrest and apoptosis of SKOV3 cells in vivo and in vitro, and pcDNA-SRC can reverse the effect of miR-485-5p mimics on ovarian cancer. Our findings suggest that miR-485-5p could inhibit the progression of ovarian cancer by targeting SRC, which might be a new target for ovarian cancer therapy as the SRC inhibitor.